| HRA000748
(Controlled Access)
|
The infants diagnosed with EEs were enrolled from a single pediatric epilepsy center between January 2018 and February 2020. Demographic and clinical data were collected. In WES data, the pathogenic SNVs were identified through an in-house pipeline, and pathogenic CNVs were identified by CNVkit. The diagnostic rate were evaluated and the molecular findings were characterized.The application of detecting both SNPs/Indels and CNVs in single test based on WES yielded a high diagnosis rate in EEs. WES may be severed as a first-tier test with cost-effective benefit in EEs. |
